Structure analyses of HIV-1 reverse transcriptase with HBV-associated 4M/4MA/5MB mutations with bound DNA:dGTP

Yoshiaki YASUTAKE1,2,*, Shin-ichiro HATTORI3, Noriko TAMURA1, Kenji MAEDA3, Hiroaki MITSUYA3,4,5
1Bioproduction Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Sapporo 062-8517, Japan
2Computational Bio Big-Data Open Innovation Laboratory, AIST, Tokyo 169-8555, Japan
3National Center for Global Health and Medicine (NCGM) Research Institute, Tokyo 162-8655, Japan
4National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD 20892, USA.
5Kumamoto University Hospital, Kumamoto 860-8556, Japan.

1 Introduction
Hepatitis B virus (HBV) polymerase (Pol) is a pivotal enzyme for viral replication, while its three-dimensional structure has not been determined because of its unstable and insoluble properties. Therefore, we selected HIV-1 RT with HBV-associated amino acid substitutions at nucleotide-binding site (N-site) as a surrogate for experimental structural studies of HBV Pol. We have previously shown that HIV-1 with the three HBV-associated amino-acid substitutions (3MB: Q151M/Y115F/F116Y) is highly susceptible to the anti-HBV nucleoside analogs (NAs), entecavir (ETV) and lamivudine (3TC). Additional mutations M184V and F160M, which are known to confer ETV/3TC-resistance on HBV RT (M204V and L180M in HBV RT), significantly decreases the susceptibility of HIV-1 RT3MB to ETV and 3TC. The structures of HIV RT3MB, RT3MB/M184V and RT3MB/M184V/F160M provided insights into the ETV/3TC binding and drug resistant mechanisms [1, 2]. In this study, we newly selected 163/L74 near the nucleotides of the template strand that form base pairs with the NAs/dNTPs, created HIV-1 RT mutants with HBV-associated 3MB/L74V (4M), 3MB/I63V (4MA) and 3MB/L74V/I63V (5MB), and determined their structures in complex with DNA:dGTP.

2 Experiment
HIV-1 RT3M, RT4MA and RT5MB were overproduced using Escherichia coli BL21(DE3)-RIL, and purified by Ni-affinity and ion-exchange chromatography as described previously [1, 3]. A template-primer-mimic 38-mer DNA aptamer [3] was used for preparation of RT:DNA complex. After mixing RT and DNA, samples were loaded on gel-filtration chromatography [1]. The HIV-1 RT3M/4MA/5MB in complex with DNA were crystallized by the hanging-drop vapor-diffusion method at 20°C, with a reservoir solution containing bis-Tris-HCl pH 6.0, ammonium di-hydrogen citrate, MgCl2, PEG 6000, glycerol, and sucrose. Crystals were soaked in a cryoprotectant solution consisting of 25% glycerol, 15% PEG 6000, and 15% sucrose supplemented with dGTP, and then flash-cooled in liquid nitrogen at 100 K.

3 Results and Discussion
We have solved the structures of HIV-1 RT3M, RT4MA and RT5MB in complex with DNA:dGTP at resolution of 2.31 Å, 2.22 Å, and 2.24 Å, respectively. These structural data are the highest resolution of any previously reported HIV-1 RT:DNA complex, and provide accurate atomic information on the side chains of all amino acids forming the N-site. The Fo-Fc map clearly showed the bound dGTP-Mg2+ within the active site (Fig. 1). The model refinement and the detailed structural comparison with those of previously reported RTWT and RT3MB are in progress.

Fig. 1: Unbiased Fo-Fc omit map for the bound dGTP-Mg2+ within the N-site structure of HIV-1 RT3MB. The mutated residues are labelled.

Acknowledgement
The authors would like to thank the beamline staff at the Photon Factory for their assistance during X-ray diffraction experiments. This study was partly supported by a grant from the Program on the Innovative Development and Application of New Drugs for Hepatitis...
B from the Japan Agency for Medical Research and Development (AMED) (JP21fk0310113). This work was also partly supported by a grant from the Japan Society for the Promotion of Science (JSPS KAKENHI; grant number: JP20K07522) and an intramural research program from the National Center for Global Health and Medicine (NCGM) (grant number: 20A-1015). Synchrotron radiation experiments at PF were supported by the Platform Project Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) from AMED.

References

* y-yasutake@aist.go.jp